Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Down 9.2 %

NASDAQ:TRVN opened at $1.48 on Friday. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The company has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $4.44. The company has a market cap of $1.27 million, a price-to-earnings ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million during the quarter. On average, analysts expect that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.